In contrast to the highly diversified acquired resistance, only a few mechanisms of adaptive resistance to RAF inhibitors have been reported in melanoma, such as ERK1/2 reactivation, upregulation of RTKs and metabolic reprogramming8. Here, MAPK3 is linked to melanoma.